CN107349318B - Blood fat reducing pericarpium trichosanthis compound and preparation method thereof - Google Patents
Blood fat reducing pericarpium trichosanthis compound and preparation method thereof Download PDFInfo
- Publication number
- CN107349318B CN107349318B CN201710604800.8A CN201710604800A CN107349318B CN 107349318 B CN107349318 B CN 107349318B CN 201710604800 A CN201710604800 A CN 201710604800A CN 107349318 B CN107349318 B CN 107349318B
- Authority
- CN
- China
- Prior art keywords
- extract
- group
- content
- allium macrostemon
- total
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 40
- 239000008280 blood Substances 0.000 title claims abstract description 40
- 150000001875 compounds Chemical class 0.000 title abstract description 25
- 230000001603 reducing effect Effects 0.000 title abstract description 16
- 238000002360 preparation method Methods 0.000 title description 7
- 239000000284 extract Substances 0.000 claims abstract description 73
- 241000304531 Allium macrostemon Species 0.000 claims abstract description 46
- 241000218989 Trichosanthes Species 0.000 claims abstract description 23
- 235000008326 Trichosanthes anguina Nutrition 0.000 claims abstract description 22
- 244000078912 Trichosanthes cucumerina Species 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 9
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 6
- 229960005305 adenosine Drugs 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 5
- 229930182490 saponin Natural products 0.000 claims description 5
- 150000007949 saponins Chemical class 0.000 claims description 5
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 4
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 4
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 229930003944 flavone Natural products 0.000 claims description 4
- 150000002212 flavone derivatives Chemical class 0.000 claims description 4
- 235000011949 flavones Nutrition 0.000 claims description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 4
- 235000013824 polyphenols Nutrition 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 229960001285 quercetin Drugs 0.000 claims description 4
- 235000005875 quercetin Nutrition 0.000 claims description 4
- 238000001228 spectrum Methods 0.000 claims description 4
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 2
- 239000003524 antilipemic agent Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 12
- 210000004185 liver Anatomy 0.000 abstract description 10
- 230000003078 antioxidant effect Effects 0.000 abstract description 7
- 230000001105 regulatory effect Effects 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 230000004060 metabolic process Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 210000002966 serum Anatomy 0.000 description 16
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 14
- 229940118019 malondialdehyde Drugs 0.000 description 14
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 7
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 210000005228 liver tissue Anatomy 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 5
- 240000006023 Trichosanthes kirilowii Species 0.000 description 4
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 229960000516 bezafibrate Drugs 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000002376 aorta thoracic Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000004177 elastic tissue Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000258745 Patiria pectinifera Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 241000975594 Trichosanthes rosthornii Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004530 effect on cardiovascular disease Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000009912 gualou xiebai baijiutang Substances 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 210000003090 iliac artery Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a blood fat reducing trichosanthes bark compound, which comprises trichosanthes bark extract and allium macrostemon extract as effective components, wherein the proportion of the trichosanthes bark extract to the allium macrostemon extract is 1:7.83-1: 3.58. The combination of the snakegourd peel extract, the allium macrostemon extract and the snakegourd peel and allium macrostemon extract can improve the blood fat metabolism of hyperlipidemic mice, and the snakegourd peel and allium macrostemon extract groups with different proportions have better effect of regulating blood fat than the snakegourd peel extract or the allium macrostemon extract which is used alone. The synergistic effect of the active ingredients in the trichosanthes bark and the allium macrostemon is demonstrated, the blood fat can be better regulated, and meanwhile, the compound has remarkable antioxidant activity and has a repairing function on the liver and the initiative.
Description
Technical Field
The invention belongs to the field of traditional Chinese medicines, and particularly relates to a blood fat reducing compound with a snakegourd peel extract and an allium macrostemon extract as main components.
Background
In modern society, with the change of life style, environment and other factors, the disease spectrum of human beings is greatly changed from the past, cardiovascular diseases become one of the main chronic diseases which harm human health, hyperlipidemia aggravates metabolic disturbance and increases the risk of cardiovascular diseases, and hyperlipidemia and complications thereof are considered as one of important social problems. Hyperlipidemia is a lifelong condition of dyslipidemia. Blood lipids can be stabilized between normal values by drug treatment, but are not cured. If the drug treatment is stopped, the blood fat concentration will be increased again. Western medicines have obvious lipid regulating effect, but clinical observation shows that the traditional Chinese medicine has the characteristics of easy rebound after use and difficult maintenance of curative effect, and has side effects of causing liver function damage and the like, so people are afraid of psychology. Therefore, there is a need to develop a functional food for reducing blood lipid with high efficiency and safety.
The pericarpium trichosanthis is the pericarp of bilateral Trichosanthes kirilowii (Trichosanthes rosthornii Harms) or the Trichosanthes kirilowii Maxim of the Cucurbitaceae family, and contains amino acids, flavonoids, triterpenes (Liu jin na, Wen Chun Xiu, Liu Ming, and the like), the research on the chemical components and the pharmacological activity of the Trichosanthes kirilowii Maxim progresses [ J ]. the traditional Chinese medicinal materials, 2013,36(5): 843-8), and the extract or the injection thereof has the functions of dilating arterioles, resisting platelet aggregation, promoting blood circulation to remove blood stasis and relieving chest distress (from Chen Xin Xiu, jin has Yu, Tangguang, newly-compiled pharmacology [ M ].17 edition, Beijing: the human health publisher, 2011.) and has certain treatment effect on cardiovascular diseases. The active components of the allium macrostemon for promoting blood circulation and removing blood stasis mainly comprise saponin and adenosine compounds (from the generation of Yao, Chenhaifeng, Wanglili. research on active substances of the traditional Chinese medicine allium macrostemon for promoting blood circulation and removing blood stasis [ C ]: the third world, the Chinese-Western medicine combination society, Guangzhou, Guangdong, China, 2007). The trichosanthes bark-allium macrostemon composition has important significance for preventing and treating cardiovascular diseases, and has safety and no toxic and side effects (from Zhouyi, 37154;, Asterina pectinifera, Weimeiling, and the like, long-term toxicity test of trichosanthes longum dropping pills [ J ]. Chinese Hospital pharmaceutical journal, 2015,35(13):1172-1179.)
The snakegourd peel extract and the allium macrostemon extract are compounded, so that the blood fat level is more remarkably reduced through multiple target spots, and the compound has remarkable antioxidant activity.
The pericarpium Trichosanthis and Bulbus Allii Macrostemi wine decoction is prepared by referring to the "Gua Lou Xiebai wine decoction" from Zhang Zhongjing jin Kui Yao L ü e, and combining the regulation mechanism and compatibility principle of natural medicines for reducing blood lipid. The two natural medicines (extracts) are combined according to a certain proportion to develop the compound preparation of snakegourd peel and allium macrostemon for reducing blood fat, and the active ingredients in the extracts achieve the optimal blood fat reducing effect through multiple targets.
Disclosure of Invention
The invention aims to provide a medicine or food, and the medicine or food contains the blood fat reducing composition.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
a blood fat reducing pericarpium trichosanthis compound comprises pericarpium trichosanthis extract and allium macrostemon extract as effective components.
The ratio of the raw materials of the snakegourd peel and the allium macrostemon is 1:7.83-1: 3.58.
The ratio of the quercetin in the snakegourd peel extract to the adenosine in the allium macrostemon extract is 1:8-1: 4. Wherein the content of total flavone in the pericarpium Trichosanthis extract is 5-6mg/g, the content of total polyphenol is 7-8mg/g, the content of total saponin is 7-8mg/g, the content of quercetin is 0.1-0.2mg/g, the content of adenosine is 0.07-0.08mg/g, and the content of total amino acid is 62-63 mg/g; the Bulbus Allii Macrostemi extract contains total flavone 2-3mg/g, total polyphenol 3-4mg/g, total saponin 19-20mg/g, adenosine 0.1-0.2mg/g, and total amino acids 26-27 mg/g.
A preparation method of a blood fat reducing pericarpium trichosanthis compound comprises the following steps:
step one, weighing dry powder of snakegourd peel and allium macrostemon respectively and placing the dry powder into different reflux bottles;
step two, respectively adding 60% ethanol with 10 times volume of the mixture, refluxing, filtering and collecting filtrate;
step three, adding 60% ethanol with the volume 10 times that of the residue obtained in the step two, refluxing, filtering, and collecting and combining filtrate;
step four, removing ethanol and water from the product obtained in the step three by using a rotary evaporator, adding a certain volume of pure water, and uniformly mixing to prepare the crude drug with the concentration of 2.1 g/mL.
The reflux time in the second step and the third step is 2 hours.
The blood fat reducing trichosanthes bark compound has antioxidant activity and double-layer blood fat reducing effect.
The antioxidant activity of the blood fat reducing trichosanthes bark compound has the following effects: obviously increase the SOD and GSH-PX activity of serum and liver tissues and reduce the MDA content of the serum and the liver tissues.
The blood fat reducing trichosanthes bark compound has the blood fat reducing effect as follows: obviously reduce the TC, TG and LDL-C levels of serum.
The invention has the beneficial effects that: the combination of the snakegourd peel extract, the allium macrostemon extract and the snakegourd peel and allium macrostemon extract can improve the blood fat metabolism of hyperlipidemic mice, and the snakegourd peel and allium macrostemon extract groups with different proportions have better effect of regulating blood fat than the snakegourd peel extract or the allium macrostemon extract which is used alone. The synergistic effect of the active ingredients in the trichosanthes bark and the allium macrostemon is demonstrated, the blood fat can be better regulated, and meanwhile, the compound has remarkable antioxidant activity and has a repairing function on the liver and the initiative.
Detailed Description
Example 1 preparation of a combination
Mixing pericarpium Trichosanthis extract and Bulbus Allii Macrostemi extract at different mass ratios listed in Table 1, adding a certain volume of pure water, mixing, and making into compound preparation with concentration of 2.1g/mL (crude drug volume).
TABLE 1 Compound composition
| Raw material ratio of trichosanthes bark to allium macrostemon | |
| Trichosanthes peel extract&Bulbus Allii Macrostemi extract 4 groups | 1:7.83 |
| Trichosanthes peel extract&Bulbus Allii Macrostemi extract 5 groups | 1:3.58 |
Example 2 antioxidant and hypolipidemic Activity experiments
Laboratory animal
C57BL/6 mice, male, weighing about 20g, 3-5w weeks old, clean grade, were housed in the SPF grade animal house at the animal center of the salt city institute of health and occupational technology, provided by shanghai slaike laboratory animals ltd, certification No.: SCXK (Shanghai 2012-0002)
Mouse feed
The basic feed (the feed is prepared according to GB14924.3-2001 (compound feed for mice and rats of experimental animals)), and the high-fat feed is prepared according to the CFDA standard. In order to prevent the feed from being oxidized, fresh feed was prepared every week and stored in a refrigerator at-20 ℃.
Experimental materials and instruments
Bezafibrate tablet Jiangsu Tianshilibei pharmaceutical Co Ltd (national drug standard: H20010013), a peroxide dismutase (SOD) kit, a Malondialdehyde (MDA) kit and a glutathione peroxidase (GSH-PX) kit are purchased from Nanjing institute of construction. Eclipse E100 microscope japan nico.
Experimental procedure
The divided administration was carried out in accordance with Table 2, the food intake and the water intake were the same, and the administration was carried out once a day by intragastric administration, and the dosage of the intragastric solution in the groups P1, P2, P3, P4, P5, P6 and P7 was 0.2mL/10g/day [43] (corresponding to 42g/kg/day of crude drug). Blood was collected 75days later and serum was isolated for future use.
Firstly, blood sample collection: blood is collected after 75days of medication, serum is collected after centrifugation at 3000rpm at low temperature, and the serum is stored at 80 ℃ below zero and is used for blood biochemical detection. The blood biochemical detection indexes are as follows: triglycerides (TG), Total Cholesterol (TC), low density lipoprotein (LDL-C) and high density lipoprotein (HDL-C).
Measurement of in vivo antioxidant index: detecting the activity of superoxide dismutase and glutathione peroxidase and the content of malondialdehyde by serum and liver tissues. Referring to the instruction provided by the establishment research, the reagent adopts an hydroxylamine method to determine the activity of SOD, GSH-Px and the content of MDA.
Thirdly, collecting according to samples: after the anesthetized mouse is perfused by normal saline, taking the heart and blood vessels (from the aortic arch to the common renal and iliac arteries), flushing with normal saline, horizontally cutting the blood vessels of the aorta with the length of 1cm at the lower edge of the aortic arch, and soaking the aorta in 4% paraformaldehyde for fixation; heart tissue is embedded in OCT and stored at-80 deg.C for further use; after stripping the liver, heart and kidney of the mouse, the contaminated blood was washed away with physiological saline, then blotted with filter paper, weighed, and the liver was fixed by soaking in 4% paraformaldehyde.
Fourthly, pathological observation: the fixed samples of liver and heart outflow tracts were subjected to paraffin embedding and HE staining.
TABLE 2 grouping and administration
| Grouping | Dosage form |
| Control group | Conventional feed |
| High fat group | High-fat feed |
| High fat and normal saline | Same volume |
| High fat and bezafibrate tablet | 117mg/kg/d |
| High fat + P1 | Trichosanthes peel extract |
| High fat + P2 | Allium macrostemon extract |
| High fat + P3 | Snakegourd peel&Raw material of longstamen onion bulb 1:1.50 |
| High fat + P4 | Snakegourd peel&Raw material of longstamen onion bulb 1:7.83 |
| High fat + P5 | Snakegourd peel&Raw material of longstamen onion bulb 1:3.58 |
| High fat + P6 | Snakegourd peel&Raw material of allium macrostemon 2.10:1 |
| High fat + P7 | Snakegourd peel&Bulbus Allii Macrostemi raw material 7.69:1 |
(1) Results
Firstly, modeling index determination
As shown in table 3, after the model group was fed with the high-fat diet for 4 weeks, the serum triglyceride was increased, the serum total cholesterol and the low-density lipoprotein cholesterol were increased, and the differences were significant, and the establishment of the model was determined.
TABLE 3 mouse index Change after modeling
(in comparison with conventional feed, denotes P <0.01)
② influence on blood fat of mice
From table 4, it can be seen that the compatibility of different compounds of trichosanthes bark extract, allium macrostemon extract and trichosanthes bark and allium macrostemon extract all have the function of regulating the blood fat of the experimental hyperlipidaemia mouse, and the function of the compound compatibility preparation of trichosanthes and allium macrostemon extract is better than that of the trichosanthes bark extract or allium macrostemon extract which is singly used from the aspect of blood fat indexes.
TABLE 4 Trichosanthes kirilowii Maxim extract, Allium macrostemon extract and Compound group for blood lipid of mouseThe effect (n-10,
)mmol/L
(note: a is P >0.05, b is 0.05> P.gtoreq.0.01, c is P <0.01)
Influence on antioxidation in mice
TABLE 5 SOD activity, GSH-PX activity and MDA content in serum and tissue of each group of mice
(note: a is p >0.05, b is 0.05> p.gtoreq.0.01, c is p <0.01)
The SOD in serum and tissue samples of different groups is shown in table 5, and the physiological saline has no significant difference with the high-fat group, which indicates that the SOD is not affected by gastric lavage. SOD in the serum of mice in the high-fat group is lower than that in the conventional feed group, but has no significant difference. Compared with the pericarpium trichosanthis extract group P1 and the allium macrostemon extract group P2, the SOD of the pericarpium trichosanthis and allium macrostemon extract compound group except the P3 group is reduced, and the SOD of the pericarpium trichosanthis and allium macrostemon extract compound group is increased, wherein the SOD of the P4 group, the P5 group, the P6 group and the SOD of the P7 group are respectively increased by 1.75%, 6.56%, 5.52% and 12.87%. The SOD value of the P7 group is the highest, and is significantly different from that of the high-fat group, and the SOD is increased by 13.20%.
The SOD in the liver tissue of the mice in the high-fat group is low in the conventional feed group, and has significant difference. The SOD values of other groups are higher than those of a high-fat group, except for a P3 group, the SOD values of a bezafibrate group are increased by 7.52 percent, a P1 group is increased by 5.26 percent, a P2 group is increased by 7.52 percent, a P3 group is increased by 2.26 percent, a P4 group is increased by 27.82 percent, a P5 group is increased by 18.05 percent, a P6 group is increased by 8.27 percent, a P7 group is increased by 12.78 percent, and the SOD values of a trichosanthes peel and allium macrostemon extract compound group are higher than those of a trichosanthes peel extract group P1 and an allium macrostemon extract group P2, wherein the SOD value of the P4 group is the highest.
ii GSH-PX in serum and tissue samples of different groups is shown in Table 5, and the difference between physiological saline and high fat group is not significant, which indicates that the gavage has no influence on GSH-PX. GSH-PX in the serum of mice in the high-fat group is lower than that in the conventional feed group, but has no significant difference. Compared with a high-fat group, the bezafibrate group, the P1 group, the P2 group, the P3 group, the P4 group, the P5 group, the P6 group and the P7 group are respectively increased by 50.92%, 10.93%, 9.20%, 39.89%, 91.41%, 117.18%, 19.63% and 23.31%, wherein the P5 group is obviously different from the high-fat group. The GSH-PX value of the pericarpium Trichosanthis and Bulbus Allii Macrostemi extract compound group is higher than that of the pericarpium Trichosanthis extract group P1 and that of the Bulbus Allii Macrostemi extract group P2, wherein the GSH-PX of the P5 group is the highest.
GSH-PX in liver tissues of mice in the high-fat group is lower than that of the conventional feed group, and has significant difference. Compared with a high-fat group, the bezafibrate group, the P1 group, the P2 group, the P3 group, the P4 group, the P5 group, the P6 group and the P7 group are respectively increased by 36.81%, 1.49%, 24.04%, 28.70%, 14.07%, 33.64% and 7.74%, wherein the bezafibrate group, the P2 group, the P3 group, the P4 group and the P6 group have significant differences from the high-fat group. The GSH-PX values of the pericarpium Trichosanthis and Bulbus Allii Macrostemi extract compound groups P3 and P6 are higher than those of pericarpium Trichosanthis extract group P1 and Bulbus Allii Macrostemi extract group P2, wherein GSH-PX in P6 group is highest but lower than that of bezafibrate group.
iii the MDA in serum and tissue samples of different groups is shown in Table 5, and the physiological saline has no significant difference with the high-fat group, which indicates that the gavage has no influence on the MDA. MDA in the serum of mice in the high-fat group is higher than that in the conventional feed group, and significant difference exists. Compared with the high fat group, the bezafibrate group, the P1 group, the P2 group, the P4 group, the P5 group, the P6 group and the P7 group were decreased by 38.52%, 9.02%, 7.38%, 17.21%, 24.59%, 18.03%, 27.04%, and the P3 group was increased by 13.11%, respectively. The bezafibrate group, the P4 group, the P5 group and the P7 group have significant differences from the high fat group. The MDA values of the P4, P5, P6 and P7 groups of the trichosanthes bark and allium macrostemon extract compound group are all lower than those of the P1 and the P2 groups of the trichosanthes bark extract and allium macrostemon extract, wherein the MDA of the P7 group is lowest, and the MDA of the P5 group is next. MDA in the tissues of mice in the high-fat group was lower than that in the conventional diet group, MDA in the other groups except P6 group was lower than that in the high-fat group, and others were higher than that in the high-fat group, which may be related to impurities in the tissues. The P6 group decreased by 33.98%.
Fourthly, pathological observation results of liver and aorta
According to the observation of a liver histopathology microscope (20X) of a hyperlipidemic mouse, the liver and liver lobule structures of a hyperlipidemic mouse are less clear, the mouse has moderate to severe hepatocellular steatosis, different-sized fat bubbles appear in cytoplasm, the volumes of hepatocytes become large and round, cell nuclei are squeezed to one side, the shape is changed, hepatic sinuses are obviously narrowed or disappeared, the staining of hepatocytes is shallower than that of normal cells, the cytoplasm is lightly stained, most of acini shows punctiform or focal necrosis, medium and mild inflammatory cell infiltration is carried out in a convergent area, no obvious hepatic fibrosis is found, cholesterol crystallization appears near the central veins of most hepatic lobules, the liver tissue structure of a conventional feed mouse is stable, hepatic cords are radially arranged around the central veins, the outline of the hepatic lobules is clear, the hepatic cells show polygons, the cell boundaries are clear, and the nucleus is round, intermediate to the cell, abundant cytoplasm; the bezafibrate mouse has a complete liver cell structure, the degeneration of a cell water sample disappears, bubbles are reduced, and the liver cell is deeply colored; the livers of the mice in the P1-P7 groups are slightly improved, wherein the best group is P4, and the next group is P5.
The hyperlipidemia mice have the advantages that blood vessel pathological microscope (40X) observes that the blood vessel intima of the hyperlipidemia mice thickens and rises, part of endothelial cells decline, the space under the endothelium becomes larger, the intima has edema phenomenon and has foam infiltration cells, smooth muscle cells transfer to the subcutaneous part of the endothelium, the media membrane becomes thicker obviously, the smooth muscle cells increase and are irregularly perpendicular to the intima and then turn to the intima, the tissue morphology changes, the blood vessel of the mice fed by the conventional feed is clear, the intima is smooth, the structure of the endothelial cells is stable, lipid and inflammatory cells do not infiltrate under the endothelium, the structures of the media and the adventitia are clear, the media layer consists of elastic fiber membranes, a plurality of prismatic nucleus smooth muscle cells and a few fiber components exist among the elastic fiber membranes, the adventitia is thinner, and no fat cells appear; the bezafibrate group has the advantages that the vascular structure state is improved and repaired, the layers are clear, the intima is smooth, and the endothelial cell morphology is continuous and intact; the P1-P7 groups all improved.
Claims (4)
1. A hypolipidemic agent, which is characterized in that: the medicine is composed of effective components of snakegourd peel extract and allium macrostemon extract; the pericarpium trichosanthis extract and the allium macrostemon extract in the medicine are identified by IR fingerprint spectra, wherein the peak ranges of the pericarpium trichosanthis extract spectra are as follows: 533.80-3415.61 cm-1(ii) a The peak range of the spectrum of the allium macrostemon extract is as follows: 597.55-3489.77 cm-1(ii) a The ratio of the raw materials of the snakegourd peel and the allium macrostemon is 1:7.83-1: 3.58; the ratio of the quercetin in the trichosanthes bark extract to the adenosine in the allium macrostemon extract is 1:8-1: 4; wherein the content of total flavone in the pericarpium Trichosanthis extract is 5-6mg/g, the content of total polyphenol is 7-8mg/g, the content of total saponin is 7-8mg/g, the content of quercetin is 0.1-0.2mg/g, the content of adenosine is 0.07-0.08mg/g, and the content of total amino acid is 62-63 mg/g; the content of total flavone in the allium macrostemon extract is 2-3mg/g, the content of total polyphenol is 3-4mg/g, the content of total saponin is 19-20mg/g, the content of adenosine is 0.1-0.2mg/g, and the content of total amino acid is 26-27 mg/g; wherein the pericarpium Trichosanthis extract and Bulbus Allii Macrostemi extract are obtained by extracting with 60% ethanol.
2. A process for producing a blood lipid lowering agent according to claim 1, comprising the steps of:
step one, weighing dry powder of snakegourd peel and allium macrostemon respectively and placing the dry powder into different reflux bottles;
step two, respectively adding 60% ethanol with 10 times volume of the mixture, refluxing, filtering and collecting filtrate;
step three, adding 60% ethanol with the volume 10 times that of the residue obtained in the step two, refluxing, filtering, and collecting and combining filtrate; step four, removing ethanol and water from the product obtained in the step three by using a rotary evaporator, adding a certain volume of pure water, and uniformly mixing to prepare the crude drug with the concentration of 2.1 g/mL.
3. The process for preparing a hypolipidemic agent according to claim 2, wherein the reflux time in step two is 2 hours.
4. The method for preparing a blood lipid lowering drug according to claim 2, wherein the reflux time in step three is 2 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710604800.8A CN107349318B (en) | 2017-07-25 | 2017-07-25 | Blood fat reducing pericarpium trichosanthis compound and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710604800.8A CN107349318B (en) | 2017-07-25 | 2017-07-25 | Blood fat reducing pericarpium trichosanthis compound and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107349318A CN107349318A (en) | 2017-11-17 |
| CN107349318B true CN107349318B (en) | 2020-11-20 |
Family
ID=60284806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710604800.8A Expired - Fee Related CN107349318B (en) | 2017-07-25 | 2017-07-25 | Blood fat reducing pericarpium trichosanthis compound and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107349318B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1280851A (en) * | 1999-07-15 | 2001-01-24 | 沈阳药科大学 | Chinese-medicinal composition containing Chinese onion for improving hyperlipomia |
| CN1486707A (en) * | 2002-09-30 | 2004-04-07 | 吉林省东方制药有限公司 | Method of extracting medicine for hyperlipemia from Chinese onion bulb |
| CN1927329A (en) * | 2006-09-11 | 2007-03-14 | 天津大学 | Medicine for curing cardiovascular disease and its preparation method |
| CN101224274A (en) * | 2008-01-10 | 2008-07-23 | 江苏吴中苏药医药开发有限责任公司 | Medicine compounds of pericarp trichosanthis, longstamen onion bulb extract and preparing method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102058757B (en) * | 2010-11-25 | 2012-07-04 | 代龙 | Traditional Chinese medicinal composition for treating cardiovascular diseases and preparation method thereof |
-
2017
- 2017-07-25 CN CN201710604800.8A patent/CN107349318B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1280851A (en) * | 1999-07-15 | 2001-01-24 | 沈阳药科大学 | Chinese-medicinal composition containing Chinese onion for improving hyperlipomia |
| CN1486707A (en) * | 2002-09-30 | 2004-04-07 | 吉林省东方制药有限公司 | Method of extracting medicine for hyperlipemia from Chinese onion bulb |
| CN1927329A (en) * | 2006-09-11 | 2007-03-14 | 天津大学 | Medicine for curing cardiovascular disease and its preparation method |
| CN101224274A (en) * | 2008-01-10 | 2008-07-23 | 江苏吴中苏药医药开发有限责任公司 | Medicine compounds of pericarp trichosanthis, longstamen onion bulb extract and preparing method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 瓜蒌、薤白降脂作用的析因研究;贺立勍;《湖南中医药导报》;20020430;第8卷(第4期);第205、207页，尤其是第205页摘要及第1.2节 * |
| 瓜蒌皮与薤白提取物中主要物质含量测定条件的优化;杨丽等;《食品工业》;20170630;第38卷(第6期);第200页左栏第1段，第201页左栏1.3.2.1 样品溶液的制备 * |
| 贺立勍.瓜蒌、薤白降脂作用的析因研究.《湖南中医药导报》.2002,第8卷(第4期),第205、207页，尤其是第205页摘要及第1.2节. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107349318A (en) | 2017-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2149379B1 (en) | Use of a vegetable drug composition in the manufacturing of a pharmaceutical preparation for the treatment of portal hypertension caused by hepatocirrhosis | |
| CN107441078A (en) | A kind of pharmaceutical composition for treating diabetes and its production and use | |
| CN110833595B (en) | Traditional Chinese medicine composition for treating gout and preparation method thereof | |
| CN106038700A (en) | Application of butterflybush flower and extract in preparation of medicine for treating pulmonary heart disease | |
| CN102526423A (en) | Medicine composition for treating ischemic heart disease | |
| Sarkar et al. | Evaluation of in vitro anti diabetic activity of two mangrove plant extracts: Heritiera fomes and Sonneratia apetala | |
| KR101792875B1 (en) | A composition comprising red ginseng and lactic acid bacteria for preventing, improving or treating vascular disease | |
| CN107349318B (en) | Blood fat reducing pericarpium trichosanthis compound and preparation method thereof | |
| CN105012826A (en) | Alpinia oxyphylla leaf extract and preparation method and application thereof | |
| CN105343109B (en) | Application of the cycloastragenol in preparing liver protection and promoting hepatic injury repair medicine | |
| CN110201025B (en) | Application of cyclocarya paliurus extract in preparation of medicine for treating or preventing diabetic cardiomyopathy | |
| CN101199564A (en) | Application of sanchi flower total saponine in preparing treatment hypertension disease medicament | |
| CN113082190A (en) | Application of cardiac mixture in preparation of medicine for blocking DCM through DCM myocardial cell autophagy mechanism | |
| CN106822338A (en) | Compound of reducing blood sugar and blood fat, prevention and/or treatment diabetes and its complication and application thereof | |
| CN106942439B (en) | Cyclocarya paliurus and guava leaf blood glucose reducing tea and preparation method and application thereof | |
| CN105726624A (en) | Pharmaceutical composition for treating diabetes | |
| CN101804128B (en) | Medicine composition, and use thereof in preparing medicine for curing inflammatory enteropathy | |
| CN104069173B (en) | Treat pharmaceutical composition of liver diseases and preparation method thereof | |
| CN104127545B (en) | New application of murraya tetramera huang and extract thereof in preparation of medicines | |
| CN104784195A (en) | Antidiabetic application of dogwood iridoid glycoside | |
| CN104688800B (en) | Application of the total saponins from Cornus officinalis in the drug of preparation prevention and treatment diabetic complication | |
| CN104434940A (en) | Application of panax japonicus IV a in prevention and treatment of cardiovascular disease and complication of cardiovascular disease | |
| AU2021105462A4 (en) | Use of fructus corni nano-powder in resisting type 2 diabetes mellitus | |
| CN109985206A (en) | For preventing and treating the composition of alcoholic liver injury | |
| AU2021104015A4 (en) | Composition of nadh for relieving alcohol and protecting liver and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20201120 Termination date: 20210725 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |